CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones
The study is focused on skin of color participants who have moderate-to-severe atopic dermatitis. Atopic dermatitis, also referred to as eczema...
Phase 4
Glenn Dale, Maryland, United States and 29 other locations
The study will assess the safety and efficacy of lebrikizumab in adult and adolescent participants with moderate-to-severe atopic dermatitis (AD) pre...
Phase 3
Rockville, Maryland, United States and 41 other locations
This is a phase IIa, randomized, double-blind, placebo-controlled, multi-center proof-of-concept (POC) study in subjects with moderate to severe Atop...
Phase 2
Largo, Maryland, United States and 26 other locations
The objective of this study is to assess the efficacy and safety of upadacitinib for the treatment of adolescent and adult participants with moderate...
Phase 3
Washington, District of Columbia, United States and 179 other locations
The purpose of this study is to learn about the safety and effects of 2 study medicines (PF-07275315 and PF-07264660) for the treatment of atopic der...
Phase 2
Hunt Valley, Maryland, United States and 54 other locations
The primary objective of the study is to assess the long-term safety of dupilumab in pediatric participants with AD.The secondary objectives of the s...
Phase 3
Washington, District of Columbia, United States and 83 other locations
This is a randomized, double-blind, placebo-controlled, multi-center, phase 2 study in patients with mild to moderate Atopic Dermatitis(AD), which co...
Phase 2
Towson, Maryland, United States of America and 3 other locations
/TCI, compared with placebo in combination with TCS/TCI at Week 24, assessed using Eczema Area and Severity Index (EASI)....
Phase 3
Rockville, Maryland, United States and 234 other locations
B7451015 is a Phase 3 study to evaluate Abrocitinib with or without Topical Medications in patients aged 12 years and older who have moderate to seve...
Phase 3
Chevy Chase, Maryland, United States and 558 other locations
This is designed to assess the long-term safety and efficacy of lebrikizumab for moderate-to-severe atopic dermatitis. It will last up to 33 months.
Phase 3
Washington, District of Columbia, United States and 320 other locations
Clinical trials
Research sites
Resources
Legal